Sun Pharma gets USFDA approval for generic Prevacid

AHMEDABAD: Sun Pharmaceutical Industries Ltd. received US FDA permission for its Abbreviated New Drug Applications (ANDA) for generic version of Prevacid, Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg.

Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg are therapeutic equivalents of Takeda's Prevacid Delayed-Released Capsules. These Capsules have annual sales of approximately $430 million in the US. Lansoprazole Delayed-Release Capsules USP are indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer.